{"id":24747,"date":"2026-04-16T06:00:00","date_gmt":"2026-04-16T04:00:00","guid":{"rendered":"https:\/\/adragos-pharma.com\/?p=24747"},"modified":"2026-07-07T16:43:22","modified_gmt":"2026-07-07T14:43:22","slug":"adragos-pharma-kawagoe-signs-basic-agreement-with-towa-pharmaceutica","status":"publish","type":"post","link":"https:\/\/adragos-pharma.com\/adragos-pharma-kawagoe-signs-basic-agreement-with-towa-pharmaceutica\/","title":{"rendered":"Adragos Pharma Kawagoe signs basic agreement with Towa Pharmaceutical for strategic collaboration to support stable supply of off-patent medicines"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<div style=\"height:122px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div>\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\">April 15, 2026 Adragos Pharma Kawagoe K.K. (Headquarters: Kawagoe, Saitama; Representative Director and President: Masanori Kurogome) has signed a basic agreement with Towa Pharmaceutical Co., Ltd. (Headquarters: Kadoma, Osaka; President and CEO: Itsuro Yoshida) to establish a strategic collaboration aimed at ensuring the stable supply of off-patent pharmaceuticals. Under the agreement, Adragos Pharma will promote contract manufacturing utilizing the Kawagoe plant and secure production capacity to supply up to 1.5 billion tablets per year for Towa Pharmaceutical on a planned basis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As the importance of ensuring a stable supply of off-patent medicines continues to grow in Japan, Adragos Pharma believes that pharmaceutical contract manufac-turers have an important role to play in supporting a more sustainable supply structure. Through this collaboration with Towa Pharmaceutical, the Company aims to contribute to the broader national effort to strengthen domestic manufacturing capacity, production resilience, and long-term supply stability.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img decoding=\"async\" width=\"647\" height=\"753\" src=\"https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/04\/Screenshot-2026-04-09-134521.png\" alt=\"\" class=\"wp-image-24750\" style=\"object-fit:cover;width:344px;height:450px\" srcset=\"https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/04\/Screenshot-2026-04-09-134521.png 647w, https:\/\/adragos-pharma.com\/wp-content\/uploads\/2026\/04\/Screenshot-2026-04-09-134521-258x300.png 258w\" sizes=\"(max-width: 647px) 100vw, 647px\" \/><\/figure>\n<\/div>\n\n\n<p class=\"has-text-align-center wp-block-paragraph\"><em>Pictured: Dr. Andreas Raabe, Founder and CEO of Adragos Pharma, and Mr. Itsuro Yoshida, President and CEO of Towa Pharmaceutical Co., Ltd.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Production framework<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Leveraging this partnership, Adragos Pharma will accelerate capital investment at the Kawagoe plant and expand annual solid-dosage capacity from the current 1.0 billion tablets to 2.5 billion tablets in stages. Of this total, capacity of approximately 1.5 billion tablets will be allocated to Towa Pharmaceutical. By sharing demand and supply forecasts, the two companies will work to ensure a stable supply of medicines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Comments<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00b7<\/strong> Masanori Kurogome, Representative Director, Adragos Pharma Kawagoe K. K. \u201cOur collaboration with Towa Pharmaceutical represents an important partnership in supporting the stable supply of off-patent medicines. Through capital investment at our Kawagoe plant, we will further strengthen our production and quality assurance systems and, with qualityas our highest priority, contribute to a more stable domestic supply of medicines. At the same time, this partnership will support the continued en-hancement of our capabilities as a CDMO and our sustainable growth.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00b7 <\/strong>Dr. Andreas Raabe, Founder and CEO, Adragos Pharma \u201cThis agreement reflects the important role that specialized manufacturing partners can play in supporting the stable supply of medicines. By investing in our Kawagoe site and working closely with Towa Pharmaceutical, we aim to contribute to a stronger and more resilient supply framework for off-patent medicines in Japan.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>About Adragos Pharma<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Adragos Pharma is a fast-growing global CDMO headquartered in Munich, Germany. Leveraging a network of seven manufacturing sites across Europe and Japan, we provide end-to-end pharmaceutical services from development through commercial manufacturing to support our clients. With advanced technical exper-tise and a customer-centric approach, we deliver high-quality, reliable solutions that meet the evolving needs of the pharmaceutical industry.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>April 15, 2026 Adragos Pharma Kawagoe K.K. (Headquarters: Kawagoe, Saitama; Representative Director and President: Masanori Kurogome) has signed a basic agreement with Towa Pharmaceutical Co., Ltd. (Headquarters: Kadoma, Osaka; President and CEO: Itsuro Yoshida) to establish a strategic collaboration aimed [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":22993,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[12],"tags":[],"topics":[],"locations":[],"experts":[],"class_list":["post-24747","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/24747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/comments?post=24747"}],"version-history":[{"count":6,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/24747\/revisions"}],"predecessor-version":[{"id":26209,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/24747\/revisions\/26209"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/media\/22993"}],"wp:attachment":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/media?parent=24747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/categories?post=24747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/tags?post=24747"},{"taxonomy":"topics","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/topics?post=24747"},{"taxonomy":"locations","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/locations?post=24747"},{"taxonomy":"experts","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/experts?post=24747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}